Group 1 - The core viewpoint of the article highlights that Beijing Tianxing Medical Co., Ltd. is preparing for an IPO in Hong Kong, with its prospectus submitted on August 26, 2025, and set to expire on February 26, 2026, with CITIC Securities and Jianyin International as joint sponsors [1] - Tianxing Medical is identified as the largest domestic sports medicine company in China based on projected sales revenue for 2024, focusing on innovative medical devices for comprehensive clinical solutions in sports medicine [2] - The company offers the most comprehensive range of sports medicine products in China, with 52 products including implants, active devices, related consumables, and surgical tools, providing overall clinical solutions [2] Group 2 - As of December 31, 2022, Tianxing Medical's products were present in over 1,000 hospitals in China, and this number is expected to increase to over 3,000 by December 31, 2024, including more than 1,000 tertiary hospitals [3] - The company has 20 Class III medical devices, with 5 products being the first of their kind approved for clinical use in the Chinese market, and 10 products being the first approved among domestic brands [2] - Tianxing Medical is actively developing over 35 products in the fields of sports medicine and intelligent rehabilitation [2]
新股消息 | 天星医疗港股IPO招股书失效
智通财经网·2026-02-25 23:03